Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults

Diagnostic Molecular Pathology

Volumn 20, Issue 4, 2011, Pages 225-232

  Jha, Prerana ^a   Suri, Vaishali ^a   Singh, Geetika ^a   Jha, Pankaj ^a   Purkait, Suvendu ^a   Pathak, Pankaj ^a   Sharma, Vikas ^a   Sharma, Mehar Chand ^a   Suri, Ashish ^b   Gupta, Deepak ^b   Mahapatra, Ashok Kumar ^b   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

EGFR; GBM; IDH1; p53; PTEN

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; IDH1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GLIOBLASTOMA; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHOOL CHILD;

ADOLESCENT; ADULT; AGING; BRAIN NEOPLASMS; CHILD; CHROMOSOME ABERRATIONS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC VARIATION; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 81855213208     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31821c30bc     Document Type: Article

References (49)

1. Kanu OO, Hughes B, Di C, et al. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol. 2009; 3:39-52.
2. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64: 6892-6899. (Pubitemid 39330996)
3. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, andsurvivalinglioblastomapatients. CancerRes. 2001;61: 1122-1128. (Pubitemid 32174434)
4. Casartelli G, Dorcaratto A, Ravetti JL, et al. Survival ofhigh grade glioma patients depends on their age at diagnosis. Cancer Biol Ther. 2009;8:1719-1721.
5. Lee Y, Scheck AC, Cloughesy TF, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008;1:52.
6. Fazeny-Dorner B, Wenzel C, Veitl M, et al. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs. 2003;14:305-312. (Pubitemid 36583816)
7. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99: 467-473. (Pubitemid 37040405)
8. Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology. 2003;65:259-266. (Pubitemid 37505834)
9. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010;9:717-726.
10. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453. (Pubitemid 47339290)
11. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution ofgliomas. Cancer Sci. 2009;100:2235-2241.
12. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligoden-droglial gliomas. J Neuropathol Exp Neurol. 2005;64:479-489. (Pubitemid 40781150)
13. Kleihues P, Burger PC, Collins VP, et al. World Health Organiza-tion classification of tumours. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics. Tumors of the Nervous System. Lyon: IARC; 2007:29-39.
14. Kleihues P, Louis DN, Wiestler OD, et al. WHO grading oftumours of the central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, et al. eds. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: IARC; 2007:10-49.
15. Pollack IF, Boyett JM, Yates AJ, et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol. 2003;5: 197-207. (Pubitemid 36790349)
16. Pollack IF, Finkelstein SD, Burnham J, et al. Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort. Pediatr Neurosurg. 2003;39:114-121. (Pubitemid 36928679)
17. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346:420-427. (Pubitemid 34437697)
18. Pollack IF, Hamilton RL, Burnham J, et al. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery. 2002;50:1238-1244.
19. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of child-hood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006;105:418-424. (Pubitemid 44954773)
20. Kraus JA, Felsberg J, Tonn JC, et al. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neuro-biol. 2002;28:325-333. (Pubitemid 34989295)
21. Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, et al. Characterization of glioblastomas in young adults. Brain Pathol. 2006;16:273-286.
22. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-629. (Pubitemid 46744292)
23. Jalali R, Datta D. Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol. 2008;87:111-114
24. Korshunov A, Sycheva R, Gorelyshev S, et al. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblas-tomas ofchildhood. Mod Pathol. 2005;18:1258-1263. (Pubitemid 43079926)
25. Nakamura M, Shimada K, Ishida E, et al. Molecular pathogenesis ofpediatric astrocytic tumors. Neuro Oncol. 2007;9:113-123. (Pubitemid 46580313)
26. Suri V, Das P, Pathak P, et al. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol. 2009;11:274-280.
27. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
28. Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010;99:209-215.
29. Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from ampli-fied rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990;87:8602-8606.
30. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplifica-tion\- rearrangement in human glioblastomas. Int J Cancer. 1995;62:145-148.
31. Biernat W, Huang H, Yokoo H, et al. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 2004;14:131-136. (Pubitemid 38656384)
32. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1812.
33. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11:341-347.
34. Gravendeel LA, Kloosterhof NK, Bralten LB, et al. Segregation of non-p. R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat. 2010;31:E1186-E1199.
35. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age > 50 years. Cancer. 2005;104:825-832
36. Srividya MR, Thota B, Shailaja BC, et al. Homozygous 10q23/ PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. Neuropathology. 2010. doi: 10.1111/j.1 440-1789.2010.01178.x. [Epub ahead ofprint].
37. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblasto-mas. Clin Cancer Res. 2009;15:6002-6007.
38. Felsberg J, Wolter M, Seul H, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010;119:501-507.
39. Sonoda Y, Kumabe T, Nakamura T, et al. Analysis ofIDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009;100: 1996-1998.
40. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154.
41. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27:5743-5750.
42. Bujko M, Kober P, Matyja E, et al. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients. MolDiagn Ther. 2010;14:163-169.
43. Xie D, Zeng YX, Wang HJ, et al. Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway. Acta Neuropathol. 2005;110: 481-489. (Pubitemid 41672341)
44. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217-223.
45. Fults D, Brockmeyer D, Tullous MW, et al. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res. 1992;52:674-679.
46. Sonoda Y, Murakami Y, Tominaga T, et al. Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res. 1996;87: 363-367. (Pubitemid 26147849)
47. Voesten AM, Bijleveld EH, Westerveld A, et al. Fine mapping of a region of common deletion on chromosome arm 10p in human glioma. Genes Chromosomes Cancer. 1997;20:167-172. (Pubitemid 27431141)
48. Kon H, Sonoda Y, Kumabe T, et al. Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas. Oncogene. 1998;16: 257-263. (Pubitemid 28045112)
49. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene. 2008;27:5416-5430.